# A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

> **NCT02025907** · PHASE4 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 218 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin, 100 mg
- **DRUG:** Canagliflozin, 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02025907
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2016-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02025907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02025907, "A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02025907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*